Other Income & Expense
Unrealized Gain (Loss) on Equity Securities
Neurocrine Biosciences Unrealized Gain (Loss) on Equity Securities decreased by 17.3% to $25.3M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 182.7%, from -$30.6M to $25.3M. Over 3 years (FY 2021 to FY 2024), Unrealized Gain (Loss) on Equity Securities shows a downward trend with a 21.1% CAGR.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryOther
SignalContext dependent
VolatilityVolatile
First reportedQ1 2017
Last reportedQ1 2026May 5, 2026
How to read this metric
Fluctuations reflect market conditions rather than operational performance, requiring investors to adjust net income to see true business earnings.
Detailed definition
Unrealized gain or loss on equity securities reflects the change in the fair market value of equity investments held by...
Peer comparison
Common for companies with large treasury portfolios or strategic equity stakes in other biotech firms.
Metric ID:
wmt_unrealized_gain_loss_equity_securitiesHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0 | -$8.2M | $28.4M | $19.9M | -$7.4M | $11.1M | $7.2M | $2.2M | $37.3M | -$40.1M | $29M | $1.6M | -$19.9M | -$16.9M | -$1.9M | -$30.6M | -$6.7M | $30.6M | $25.3M |
| QoQ Change | — | — | +446.3% | -29.9% | -137.2% | +250.0% | -35.1% | -69.4% | >999% | -207.5% | +172.3% | -94.5% | <-999% | +15.1% | +88.8% | <-999% | +78.1% | +556.7% | -17.3% |
| YoY Change | — | — | — | — | — | +235.4% | -74.6% | -88.9% | +604.1% | -461.3% | +302.8% | -27.3% | -153.4% | +57.9% | -106.6% | <-999% | +66.3% | +281.1% | +182.7% |
Range-$40.1M – $37.3M
Avg YoY Growth-85.3%
Median YoY Growth+15.3%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|
| Reportable Segment | -$30.6M | -$6.7M | $30.6M | $25.3M |
| Total | -$30.6M | -$6.7M | $30.6M | $25.3M |
Unrealized Gain (Loss) on Equity Securities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's unrealized gain (loss) on equity securities?
- Neurocrine Biosciences (NBIX) reported unrealized gain (loss) on equity securities of $25.3M in Q1 2026.
- How has Neurocrine Biosciences's unrealized gain (loss) on equity securities changed year-over-year?
- Neurocrine Biosciences's unrealized gain (loss) on equity securities increased by 182.7% year-over-year, from -$30.6M to $25.3M.
- What is the long-term trend for Neurocrine Biosciences's unrealized gain (loss) on equity securities?
- Over 3 years (2021 to 2024), Neurocrine Biosciences's unrealized gain (loss) on equity securities has grown at a 21.1% compound annual growth rate (CAGR), from $20.9M to -$37.1M.
- What does unrealized gain (loss) on equity securities mean?
- Changes in the value of stock investments that have not yet been sold.